Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 36, 2011, Pages 14926-14931

  Papin, James F ^a,e   Verardi, Paulo H ^c   Jones, Leslie A ^a   Monge Navarro, Francisco ^a,f   Brault, Aaron C ^a,g   Holbrook, Michael R ^d,h   Worthy, Melissa N ^d   Freiberg, Alexander N ^d   Yilma, Tilahun D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GC GLYCOPROTEIN; GN GLYCOPROTEIN; RECOMBINANT RIFT VALLEY FEVER VACCINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; IMMUNITY; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RIFT VALLEY FEVER; VERO CELL;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; GLYCOPROTEINS; HELA CELLS; HUMANS; MICE; MICE, SCID; PAPIO CYNOCEPHALUS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VERO CELLS; VIRAL PROTEINS; VIRAL VACCINES;

ANIMALIA; MUS; PAPIO; RIFT VALLEY FEVER VIRUS; VACCINIA VIRUS;

EID: 80052567032     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1112149108     Document Type: Article

References (51)

1. Fauquet C (2005) Virus Taxonomy: Classification and Nomenclature of Viruses: Eighth Report of the International Committee on the Taxonomy of Viruses (Elsevier Academic Press, San Diego, CA), pp viii, 1259 pp.
2. Fields BN, Knipe DM, Howley PM (2007) Fields Virology (Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia), 5th Ed.
3. Giorgi C, et al. (1991) Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology 180(2):738-753.
4. Collett MS (1986) Messenger RNA of the M segment RNA of Rift Valley fever virus. Virology 151(1):151-156.
5. Collett MS, et al. (1985) Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus. Virology 144(1):228-245.
6. Müller R, Poch O, Delarue M, Bishop DH, Bouloy M (1994) Rift Valley fever virus L segment: Correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol 75(6):1345-1352.
7. Zamoto-Niikura A, Terasaki K, Ikegami T, Peters CJ, Makino S (2009) Rift valley fever virus L protein forms a biologically active oligomer. J Virol 83(24):12779-12789.
8. Daubney R, Hudson JR, Garnham PC (1931) Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J Path Bact 34(2): 545-579.
9. Easterday BC (1965) Rift Valley fever. Adv Vet Sci 10:65-127.
10. Coetzer JA (1977) The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 44(4):205-211.
11. Madani TA, et al. (2003) Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37(8):1084-1092.
12. Birtch SC, Linthicum KJ (2007) Developing a research agenda and a comprehensive national prevention and response plan for Rift Valley fever in the United States. Emerg Infect Dis 13:e1. Available from http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2828099/.
13. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ (2009) Rift Valley fever virus. J Am Vet Med Assoc 234(7):883-893.
14. Smithburn KC (1949) Rift Valley fever; The neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30(1):1-16.
15. Caplen H, Peters CJ, Bishop DH (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66(10):2271-2277.
16. Vialat P, Muller R, Vu TH, Prehaud C, Bouloy M (1997) Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 52(1):43-50.
17. Verardi PH, et al. (2002) Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. J Virol 76(2):484-491.
18. Yilma T, et al. (2003) Inexpensive vaccines and rapid diagnostic kits tailor-made for the global eradication of rinderpest, and technology transfer to Africa and Asia. Dev Biol (Basel) 114:99-111.
19. Mackett M, Smith GL, Moss B (1982) Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79(23):7415-7419.
20. Falkner FG, Moss B (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64(6):3108-3111.
21. Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23(6):1094-1097.
22. Yilma T (1994) Genetically engineered vaccines for animal viral diseases. J Am Vet Med Assoc 204(10):1606-1615.
23. Yilma T, McGuire TC, Perryman LE (1982) Preliminary characterization of equine interferons and their antiviral activities on bovine, ovine, and human cells. J Interferon Res 2(3):363-370.
24. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD (2001) Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 75(1):11-18.
25. Niklasson BS, Meadors GF, Peters CJ (1984) Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol Microbiol Immunol Scand [C] 92(4):197-200.
26. Dungu B, et al. (2010) Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28(29):4581-4587.
27. Pittman PR, et al. (1999) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: A 12-year experience. Vaccine 18(1-2):181-189.
28. Schmaljohn CS, et al. (1989) Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170(1):184-192.
29. Näslund J, et al. (2009) Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385(2):409-415.
30. Spik K, et al. (2006) Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24(21):4657-4666.
31. Wallace DB, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24(49-50):7181-7189.
32. Collett MS, et al. (1987) Protective subunit immunogens to Rift Valley fever virus from bacteria and recombinant vaccinia virus. Biology of Negative Strand Viruses, eds Mahy BWJ, Kolakofsky D (Elsievier Science Publishers, Amsterdam), pp 321-329.
33. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinasenegative phenotype. Nature 317(6040):813-815.
34. Chan KS, Verardi PH, Legrand FA, Yilma TD (2005) Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus. Proc Natl Acad Sci USA 102 (24):8734-8739.
35. Giavedoni LD, et al. (1992) Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci USA 89(8):3409-3413.
36. Jones L, et al. (2000) Enhanced safety and efficacy of live attenuated SIV vaccines by prevaccination with recombinant vaccines. J Med Primatol 29(3-4):231-239.
37. Jones L, Tenorio E, Gorham J, Yilma T (1997) Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus. Am J Vet Res 58(6):590-593.
38. Legrand FA, et al. (2004) Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol 78(6): 2770-2779.
39. Earl PL, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428(6979):182-185.
40. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93(21):11341-11348.
41. Ober BT, et al. (2002) Immunogenicity and safety of defective vaccinia virus lister: Comparison with modified vaccinia virus Ankara. J Virol 76(15):7713-7723.
42. Taylor J, et al. (1992) Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187(1):321-328.
43. Hunter P, Erasmus BJ, Vorster JH (2002) Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 69(1):95-98.
44. Saluzzo JF, Smith JF (1990) Use of reassortant viruses to map attenuating and temperature- sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8(4): 369-375.
45. Bird BH, et al. (2008) Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82(6): 2681e2691.
46. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J (2010) Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41(6):61.
47. Legrand FA, et al. (2005) Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci USA 102(8):2940-2945.
48. Chakrabarti S, Brechling K, Moss B (1985) Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5(12):3403-3409.
49. Cao JX, Upton C (1997) gpt-gus fusion gene for selection and marker in recombinant poxviruses. Biotechniques 22(2):276-278.
50. Hammond JM, Oke PG, Coupar BE (1997) A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods 66(1):135-138.
51. Mandell RB, et al. (2010) A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397(1): 187-198.